Tardive Dyskinesia - Pipeline Review, H2 2014 On 14th January 2015
Tardive Dyskinesia - Pipeline Review, H2 2014, provides an overview of the Tardive Dyskinesias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tardive Dyskinesia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-tardivedyskinesia-pipeline-review-h2-2014-151296
Scope - The report provides a snapshot of the global therapeutic landscape of Tardive Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tardive Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tardive Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industryspecific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tardive Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Tardive Dyskinesia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Tardive Dyskinesia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table of Content List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Tardive Dyskinesia Overview 6 Therapeutics Development 7 Pipeline Products for Tardive Dyskinesia - Overview 7 Pipeline Products for Tardive Dyskinesia - Comparative Analysis 8 Tardive Dyskinesia - Therapeutics under Development by Companies 9 Tardive Dyskinesia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Tardive Dyskinesia - Products under Development by Companies 13 Tardive Dyskinesia - Companies Involved in Therapeutics Development 14 Auspex Pharmaceuticals, Inc. 14 Contera Pharma ApS 15 Medicure Inc. 16 Neurocrine Biosciences, Inc. 17 Synchroneuron Inc. 18 Tardive Dyskinesia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 26 acamprosate calcium SR - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Drugs for Tardive Dyskinesia - Drug Profile 28 Product Description 28 Mechanism of Action 28 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
R&D Progress 28 dutetrabenazine ER - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Tardoxal - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 valbenazine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Tardive Dyskinesia - Recent Pipeline Updates 33 Tardive Dyskinesia - Dormant Projects 40 Tardive Dyskinesia - Product Development Milestones 41 Featured News & Press Releases 41 Oct 30, 2014: Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia 41 Oct 30, 2014: Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI98854 in Tardive Dyskinesia 41 Oct 20, 2014: Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI98854 42 Aug 13, 2014: Medicure Provides Update on Tardoxal and TEND-TD Study 43 Jul 17, 2014: Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial for SD-809 in Tardive Dyskinesia 44 Feb 24, 2014: Synchroneuron Announces First Patient Dosed in Phase 2 Tardive Dyskinesia Clinical Trial 44 Jan 09, 2014: Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 45 Jan 06, 2014: Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study 47 Sep 09, 2013: Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia 48 Jul 01, 2013: Neurocrine Announces Completion Of Enrollment Into Kinect Study For Treatment Of Tardive Dyskinesia 51 Appendix 52 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List Of Tables Number of Products under Development for Tardive Dyskinesia, H2 2014 7 Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Tardive Dyskinesia - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 14 Tardive Dyskinesia - Pipeline by Contera Pharma ApS, H2 2014 15 Tardive Dyskinesia - Pipeline by Medicure Inc., H2 2014 16 Tardive Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2014 17 Tardive Dyskinesia - Pipeline by Synchroneuron Inc., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 25 Tardive Dyskinesia Therapeutics - Recent Pipeline Updates, H2 2014 33 Tardive Dyskinesia - Dormant Projects, H2 2014 40 List Of Figures Number of Products under Development for Tardive Dyskinesia, H2 2014 7 Number of Products under Development for Tardive Dyskinesia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Assessment by Monotherapy Products, H2 2014 19 Number of Products by Top 10 Targets, H2 2014 20 Number of Products by Stage and Top 10 Targets, H2 2014 21 Number of Products by Top 10 Mechanism of Actions, H2 2014 22 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 23 Number of Products by Stage and Top 10 Routes of Administration, H2 2014 24 Number of Products by Stage and Top 10 Molecule Types, H2 2014 25
Report Price: Licence Type
Price
$ 2000
Site License
$ 4000
Enterprise Wide Licence
$ 6000
Related Reports: Pfizer Limited, India (PFIZER) - Financial and Strategic SWOT Analysis Review Regulus Therapeutics Inc. (RGLS) - Financial and Strategic SWOT Analysis Review Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
RegeneRx Biopharmaceuticals, Inc. (RGRX) - Financial and Strategic SWOT Analysis Review RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review Regado Biosciences, Inc. (RGDO) - Financial and Strategic SWOT Analysis Review Recordati S.p.A. (REC) - Financial and Strategic SWOT Analysis Review Unichem Laboratories Ltd. (UNICHEMLAB) - Financial and Strategic SWOT Analysis Review Holista CollTech Limited (HCT) - Financial and Strategic SWOT Analysis Review Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review Raysearch Laboratories AB (RAY B) - Financial and Strategic SWOT Analysis Review
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Tardive Dyskinesia - Pipeline Review, H2 2014 http://www.jsbmarketresearch.com/healthcare-medical/r-tardive-dyskinesiapipeline-review-h2-2014-151296
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/